The media database brings together all published information on platforms and products, as well as financial and corporate news.
Join our mailing list.
06/22/2018
“The Ultra-Rapid Insulin (URI) BioChaperone® Lispro (BCLIS) shows Favorable Pharmacodynamics (PD) and Pharmacokinetics (PK) vs Faster Aspart (FIA) and Insulin Aspart (ASP) in Insulin Pumps (CSII)” (Poster 1035), presented by Dr. Bruce W. Bode, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)
06/22/2018
“BioChaperone® Lispro, une formulation ultra-rapide d’insuline lispro, améliore le contrôle glycémique post-prandial de sujets diabétiques de type 1 traités par de multiples injections quotidiennes d’insuline pendant 14 jours.” (Abstract CAD-19), presented by Dr. Grégory Meiffren, 2018, Société Francophone du Diabète (France)
06/22/2018
“Ultra-rapid BioChaperone® Lispro ameliorates postprandial blood glucose (PPG) control compared to Humalog in subjects with type 1 diabetes mellitus” (Poster PI005), presented by Dr G. Anderson, American Society for Clinical Pharmacology & Therapeutics (ASCPT)
06/15/2018
Ultra-Rapid BioChaperone® Lispro ameliorates postprandial blood glucose control compared with Humalog(R) in subjects with type 1 diabetes mellitus, Dr. Grit Anderen, 76th Scientific Sessions American Diabetes Association 10-14 June 2016, New Orleans, LO (USA)
06/14/2018
Adocia to Present Six Abstracts at the American Diabetes Association® 78th Scientific Sessions

06/11/2018
BioChaperone® Combo (BC Combo) improves postprandial glycemia vs. Humalog® Mix 75/25™ (HMx) in people with type 1 diabetes mellitus (T1DM, Dr. Steven V. Edelman, 76th Scientific Sessions American Diabetes Association 11-13 June 2016, New Orleans, LO (USA)
06/01/2018
Adocia and Tonghua Dongbao Announce Global Supply Agreements for Insulin Lispro and Insulin Glargine

05/02/2018
Adocia to hold conference call in regard to the Strategic Alliance for BioChaperone® Combo and BioChaperone® Lispro in China with Tonghua Dongbao

04/26/2018
Adocia and Tonghua Dongbao Announce a Strategic Alliance for BioChaperone®Combo and BioChaperone® Lispro in China.

04/16/2018
Adocia initiates First-in-Human Clinical Study of BioChaperone® Pramlintide Insulin in people with type 1 diabetes

02/17/2018
BioChaperone® Lispro, an Ultra-Rapid Insulin Lispro formulation improves post-prandial blood glucose control in a 14-day multiple daily insulin injection study in subjects with T2DM, Dr. Grégory Meiffren, February 14-17, 2018, ATTD, Vienna (Austria)
02/14/2018
BioChaperone® Lispro, an Ultra-Rapid Insulin Lispro formulation improves post-prandial blood glucose control in a 14-day multiple daily insulin injection study in subjects with T2DM, Dr. Grégory Meiffren, February 14-17, 2018, ATTD, Vienna (Austria)
01/25/2018
Adocia Announces Positive Topline Data From a Dose-Proportionality Study of BioChaperone® Combo in People with Type 2 Diabetes

12/06/2017
Adocia announces positive topline study results comparing ultra-rapid insulin BioChaperone® Lispro with Novolog® and Fiasp® in people with type 1 diabetes

11/20/2017
“Ultra-rapid BioChaperone® Lispro (BCLIS) Improves Postprandial Blood Glucose (PPG) Excursions vs. Insulin Lispro (LIS) in a 14-Day Treatment Study in Subjects with Type 1 Diabetes (T1DM)” (Poster 964) presented by Dr. Tim Heise, 77th Scientific Sessions of the American Diabetes Association, 9-13 June 2017 in San Diego, CA (USA)
10/20/2017
“Ultra-rapid BioChaperone® Lispro (BCLIS) Improves Postprandial Blood Glucose (PPG) Control vs. Insulin Lispro (LIS) in a14-Day Treatment Study in Subjects with Type 2 Diabetes (T2DM)” (Poster 994) presented by Dr. Tim Heise, 77th Scientific Sessions of the American Diabetes Association, 9-13 June 2017 in San Diego, CA (USA)
09/20/2017
“Proportional Dose-Exposure Relationship of Ultra-rapid BioChaperone® Lispro (BCLIS) in Healthy Japanese Subjects” (Poster 996), presented by Dr. Grégory Meiffren, 77th Scientific Sessions of the American Diabetes Association, 9-13 June 2017 in San Diego, CA (USA)
09/05/2017
Adocia Announces Two Data Presentations at the 53rd Annual Meeting of the European Association for the Study of Diabetes

06/14/2017
Adocia announces financial results for the third quarter 2017
06/09/2017
“Preclinical Efficacy of a Stable Aqueous Formulation of Human Glucagon with BioChaperone® Technology (BC GLU)” (Poster 1150), presented by Dr Grégory Meiffren, 77th Scientific Sessions of the American Diabetes Association, 9-13 June 2017 in San Diego, CA (USA)
06/09/2017
“Profil pharmacodynamique de BioChaperone® Combo, une co-formulation liquide des insulines lispro et glargine, chez des sujets diabétiques de type 2” (Abstract CAD-19), presented by Dr. Martin Gaudier, 2017, Société Francophone du Diabète (France)
06/09/2017
“L’insuline ultra-rapide BioChaperone® Lispro améliore le contrôle glycémique postprandial par rapport à Humalog® chez des sujets diabétiques de type 1” (Abstract CAD-19), presented by Dr. Grégory Meiffren, 2017, Société Francophone du Diabète (France)
06/09/2017
“BioChaperone® Combo, une co-formulation liquide des insulines lispro et glargine, présente un contrôle glycémique amélioré par rapport à un premix d’insuline.” (Abstract CAD-19), presented by Dr. Claire Megret, 2017, Société Francophone du Diabète (France)
06/07/2017
Adocia Initiates a Phase 1b Clinical Study on the Dose-Proportionality of BioChaperone® Combo in People with Type 2 Diabetes

06/06/2017
Adocia Announces Positive Topline Results from a Meal-Test Clinical Study of BioChaperone® Combo in People with Type 2 Diabetes

06/01/2017
Adocia initiates a study comparing ultra-rapid insulin BioChaperone® Lispro U100 with Fiasp® and Novolog® administered with an insulin pump

05/30/2017
Adocia Announces Six Data Presentations at the American Diabetes Association® 77th Scientific Sessions

Join our mailing list. Subscribe